Sutkowy, P.; Czeleń, P. Redox balance in cancer in the context of tumor prevention and treatment. Biomedicines 2025 , 13 , 1149..

[Nakabayashi, N.; Hirose, M.; Suzuki, R.; Suzumiya, J.; Igawa, M. How asymptomatic are early cancer patients of five organs based on registry data in Japan. Int. J. Clin. Oncol . 2018 , 23 , 999−1006..

Mun, E. J.; Babiker, H. M.; Weinberg, U.; Kirson, E. D.; Von Hoff, D. D. Tumor-treating fields: a fourth modality in cancer treatment. Clin. Cancer. Res. 2018 , 24 , 266−275..

Rallis, K. S.; Yau, T. H. L.; Sideris, M. Chemoradiotherapy in cancer treatment: rationale and clinical applications. Anticancer Res. 2021 , 41 , 1−7..

Lawrence, T. S.; Haffty, B. G.; Harris, J. R. Milestones in the use of combined-modality radiation therapy and chemotherapy. J. Clin. Oncol. 2014 , 32 , 1173−1179..

Seiwert, T. Y.; Salama, J. K.; Vokes, E. E. The concurrent chemoradiation paradigm—general principles. Nat. Clin. Pract. Oncol. 2007 , 4 , 86−100..

Nishimura, Y. Rationale for chemoradiotherapy. Int. J. Clin. Oncol. 2004 , 9 , 414−420..

McRee, A. J.; Cowherd, S.; Wang, A. Z.; Goldberg, R. M. Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncol. 2011 , 7 , 409−426..

Kaur, S.; Prasad, C.; Balakrishnan, B.; Banerjee, R. Trigger responsive polymeric nanocarriers for cancer therapy. Biomater. Sci. 2015 , 3 , 955−987..

Caster, J. M.; Wang, A. Z. Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer. Ther. Deliv. 2017 , 8 , 791−803..

Sun, H.; Wang, X.; Zhai, S. The Rational Design and Biological Mechanisms of Nanoradiosensitizers. Nanomaterials 2020 , 10 , 504..

Shi, Y.; van der Meel, R.; Chen, X.; Lammers, T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics 2020 , 10 , 7921−7924..

Pan, Y.; Liu, L.; Mou, X.; Cai, Y. Nanomedicine strategies in conquering and utilizing the cancer hypoxia environment. ACS Nano 2023 , 17 , 20875−20924..

Park, H.; Saravanakumar, G.; Kim, J.; Lim, J.; Kim, W. J. Tumor microenvironment sensitive nanocarriers for bioimaging and therapeutics. Adv. Healthc. Mater. 2021 , 10 , 2000834..

Qu, X.; Zhou, D.; Lu, J.; Qin, D.; Zhou, J.; Liu, H. Cancer nanomedicine in preoperative therapeutics: nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. Bioact. Mater. 2023 , 24 , 136−152..

Wang, X.; Niu, X.; Sha, W.; Feng, X.; Yu, L.; Zhang, Z.; Wang, W.; Yuan, Z. An oxidation responsive nano-radiosensitizer increases radiotherapy efficacy by remolding tumor vasculature. Biomater. Sci. 2021 , 9 , 6308−6324..

Wang, X.; Niu, X.; Zhang, X.; Zhang, Z.; Gao, X.; Wang, W.; Y uan, Z. Construction of an AuHQ nano-sensitizer for enhanced radiotherapy efficacy through remolding tumor vasculature. J. Mater. Chem. B 2021 , 9 , 4365−4379..

Qian, L.; Li, Q.; Ding, Z.; Luo, K.; Su, J.; Chen, J.; Zhu, G.; Gan, Z.; Yu, Q. Prodrug nanosensitizer overcomes the radiation resistance of hypoxic tumor. ACS Appl. Mater. Interfaces 2022 , 14 , 56454−56470..

Xie, Y.; Lu, X.; Wang, Z.; Liu, M.; Liu, L.; Wang, R.; Yang, K.; Xiao, H.; Li, J.; Tang, X.; Liu, H. A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma. Biomater. Sci. 2022 , 10 , 6791−6803..

Tang, X.; Du, X.; Yu, Y.; Qin, M.; Qian, L.; Zhang, M.; Yang, Y.; Yu, Q.; Gan, Z. Deep-penetrating triple-responsive prodrug nanosensitizer actuates efficient chemoradiotherapy in pancreatic ductal adenocarcinoma models. Small 2022 , 18 , 2202834..

Yao, L.; Feng, L.; Tao, D.; Tao, H.; Zhong, X.; Liang, C.; Zhu, Y.; Hu, B.; Liu, Z.; Zheng, Y. Perfluorocarbon nanodroplets stabilized with cisplatin-prodrug-constructed lipids enable efficient tumor oxygenation and chemo-radiotherapy of cancer. Nanoscale 2020 , 12 , 14764−14774..

Yang, X.; Wang, Y.; Mao, T.; Wang, Y.; Liu, R.; Yu, L.; Ding, J. An oxygen-enriched thermosensitive hydrogel for the relief of a hypoxic tumor microenvironment and enhancement of radiotherapy. Biomater. Sci. 2021 , 9 , 7471−7482..

Xu, T.; Zheng, D.; Chen, M.; Song, L.; Liu, Z.; Cheng, Y.; Zhao, Y.; Huang, L.; Li, Y.; Yang, Z.; Li, C.; Dong, B.; Jing, J.; Shi, H. A cisplatin prodrug-based self-assembling ozone delivery nanosystem sensitizes radiotherapy in triple-negative breast cancer. Acta Pharm. Sin. B 2025 , 15 , 2703−2722..

Lv, S.; Long, W.; Chen, J.; Ren, Q.; Wang, J.; Mu, X.; Liu, H.; Zhang, X.; Zhang, R. Dual pH-triggered catalytic selective Mn clusters for cancer radiosensitization and radioprotection. Nanoscale 2020 , 12 , 548−557..

Zhang, R.; Chen, L.; Liang, Q.; Xi, J.; Zhao, H.; Jin, Y.; Gao, X.; Yan, X.; Gao, L.; Fan, K. Unveiling the active sites on ferrihydrite with apparent catalase-like activity for potentiating radiotherapy. Nano Today 2021 , 41 , 101317..

Yang, C.; Mi, X.; Su, H.; Yang, J.; Gu, Y.; Zha ng, L.; Sun, W.; Liang, X.; Zhang, C. GE11-PDA-Pt@USPIOs nano-formulation for relief of tumor hypoxia and MRI/PAI-guided tumor radio-chemotherapy. Biomater. Sci. 2019 , 7 , 2076−2090..

Zhang, R.; Guo, L.; Li, Q.; Liang, Y.; Liao, Y.; Xu, H.; Liu, C.; Zhou, G.; Wang, L.; Xu, S.; Yuan, M. Biodegradable carrier-free nanomedicine via self-assembly of pure drug molecules for triple sensitization of radiotherapy. ACS Nano 2025 , 19 , 16355−16371..

Wang, H.; Jia, D.; Yuan, D.; Yin, X.; Yuan, F.; Wang, F.; Shi, W.; Li, H.; Zhu, L.; Fan, Q. Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. J. Nanobiotechnol. 2021 , 19 , 138..

Zhang, L.; Du, X.; Li, Q.; Qian, L.; Chen, J.; Liu, C.; Yu, Q.; Gan, Z. A multimodal therapeutic nanoplatform overcoming tumor hypoxia heterogeneity for improved tumor chemoradiotherapy. Adv. Funct. Mater. 2022 , 32 , 2204629..

Yu, S.; Jiang, Y.; Li, Q.; Li, M.; Su, J.; Lai, S.; Gan, Z.; Ding, Z.; Yu, Q. Nano-sensitizer with self-amplified drug release and hypoxia normalization properties potentiates efficient chemoradiotherapy of pancreatic cancer. Biomaterials 2024 , 310 , 122634..

[Sun, Y.; Miao, H.;Ma, S.; Zhang, L.; You, C.; Tang, F.; Yang, C.; Tian, X.; Wang, F.; Luo, Y.; Lin, X.; Wang, H.; Li, C.; Li, Z.; Yu, H.; Liu, X.; Xiao, Y.; Gong, Y.; Zhang, J.; Quan, H.; Xie, C. FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro. Cancer Lett . 2018, 418 , 27−40..

Ma, Y.; Tang, X.; Xu, Y.; Jiang, W.; Xin, Y.; Zhao, W.; He, X.; Lu, L.; Zhan, M. Nano-enabled coordination platform of bismuth nitrate and cisplatin prodrug potentiates cancer chemoradiotherapy via DNA damage enhancement. Biomater. Sci. 2021 , 9 , 3401−3409..

Zhang, J.; Liu, Y.; Wang, X.; Du, J.; Song, K.; Li, B.; Chang, H.; Ouyang, R.; Miao, Y.; Sun, Y.; Li, Y. Nanozyme-incorporated biodegradable bismuth besoporous radiosensitizer for tumor microenvironment-modulated hypoxic tumor thermoradiotherapy. ACS Appl. Mater. Interfaces 2020 , 12 , 57768−57781..

Cheng, W.; He, S.; Chen, Q.; Song, X.; Lu, C.; Yang, H. X-ray induced persistent type I photodynamic therapy with enhanced hypoxia tolerance and chemoradiotherapy. Nano Lett. 2025 , 25 , 4549−4559..

Chen, J.; Cui, J.; Jiao, B.; Zheng, Z.; Yu, H.; Wang, H.; Zhang, G.; Lai, S.; Gan, Z.; Yu, Q. Biomimetic nanosensitizer potentiates efficient glioblastoma gene-radiotherapy through synergistic hypoxia mitigation and PLK1 silencing. ACS Appl. Mater. Interfaces 2024 , 16 , 58241−58261..

Xiao, X.; Wang, Y.; Chen, J.; Qin, P.; Chen, P.; Zhou, D.; Pan, Y. Self-targeting platinum(IV) amphiphilic prodrug nano-assembly as radiosensitizer for synergistic and safe chemoradiotherapy of hepatocellular carcinoma. Biomaterials 2022 , 289 , 121793..

Jin, Y.; Li, D.; Zheng, X.; Gao, M.; Wang, W.; Zhang, X.; Kang, W.; Zhang, C.; Wu, S.; Dai, R.; Zheng, Z.; Zhang, R. A novel activatable nanoradiosensitizer for second near-infrared fluorescence imaging-guided safe-dose synergetic chemo-radiotherapy of rheumatoid arthritis. Adv. Sci. 2024 , 11 , 2308905..

Pi, F.; Deng, X.; Xue, Q.; Zheng, L.; Liu, H.; Yang, F.; Chen, T. Alleviating the hypoxic tumor microenvironment with MnO 2 -coated CeO 2 nanoplatform for magnetic resonance imaging guided radiotherapy. J. Nanobiotechnol. 2023 , 21 , 90..

Guo, Y.; Fang, M.; Zhang, S.; Zhou, Z.; Tian, Z.; You, H.; Chen, Y.; Zhou, J.; Yang, X.; Bi, Y.; Jiang, C.; Sun, T. PROTAC-loaded nanocapsules degrading BRD4 for radio-chemotherapy sensitization in glioblastoma. Acta Pharm. Sin. B 2025 , 15 , 5050−5070..

Chen, J.; Shen, Y.; Yu, Q.; Gan, Z. Paclitaxel prodrug nanomedicine for potential CT-imaging guided breast cancer therapy. Chinese J. Polym. Sci. 2023 , 41 , 1747−1759..

[Hu, F.; Ding, Y.; Deng, C.; Zhang, J.; Qu, W.; Rong, Y.; Chen, N.; Zhou, M.; An, F. SO 2 gas potentiator engineered for self-amplifying chemo-radiotherapy in breast tumors. Chin. Chem. Lett . 2025, 112277..

Hou, M.; Zhu, K.; Hu, H.; Zheng, S.; Wu, Z.; Ren, Y.; Wu, B.; Qi, L.; Wu, D.; Xu, Y.; Yan, C.; Zhao, B. Rapid synthesis of ‘yolk-shell’-like nanosystem for MR molecular and chemo-radio sensitization. J. Control. Release 2022 , 347 , 55−67..

Luan, S.; Xie, R.; Yang, Y.; Xiao, X.; Zhou, J.; Li, X.; Fang, P.; Zeng, X.; Yu, X.; Chen, M.; Gao, H.; Yuan, Y. Acid-responsive aggregated gold nanoparticles for radiosensitization and sy nergistic chemoradiotherapy in the treatment of esophageal cancer. Small 2022 , 18 , 2200115..

Xiao, W.; Yang, X.; Wang, M.; Jiang, Z.; Zhang, H.; Gong, M.; Zhao, L.; Song, J.; Fu, Q. Enzyme-sequential responsive core-satellite nanomedicine enables activatable near-infrared-II photoacoustic imaging-guided chemotherapy cascade-enhanced radiotherapy. J. Nanobiotechnol. 2025 , 23 , 440..

Du, L.; Zhu, G.; Xu, Y.; Han, B.; Wang, Y.; Zhu, M.; Meng, Y.; Chen, H.; Yu, Z. Integrated radiochemotherapy study of ZIF-8 coated with osteosarcoma-platelet hybrid membranes for the delivery of Dbait and Adriamycin. Front. Bioeng. Biotechnol. 2023 , 11 , 1147064..

[He, C.; Zhang, Z.; Ding, Y.; Xue, K.; Wang, X.; Yang, R.; An, Y.; Liu, D.; Hu, C.; Tang, Q. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo. J. Nanobiotechnol . 2021, 19 , 1−17..

Li, X.; Yu, L.; Zhang, C.; Niu, X.; Sun, M.; Yan, Z.; Wang, W.; Yuan, Z. Tumor acid microenvironment-activated self-targeting & splitting gold nanoassembly for tumor chemo-radiotherapy. Bioact. Mater. 2022 , 7 , 377−388..

Wang, Y.; Han, X.; Zhang, S.; Wang, L.; Sun, S.; Xue, C.; Yao, T. Dual-targeted Pt@Ce-MOF nanoplatform enhances radiotherapy efficacy via tumor-specific delivery and mitochondrial dysfunction in breast cancer. Biopolymers 2025 , 116 , e70054..

Mirzaghavami, P. S.; Khoei, S.; Khoee, S.; Shirvalilou, S.; Mahdavi, S. R.; Pirhajati Mahabadi, V. Radio-sensitivity enhancement in HT29 cells through magnetic hyperthermia in combination with targeted nano-carrier of 5-flourouracil. Mater. Sci. Eng. C Mater. Biol. Appl. 2021 , 124 , 112043..

Shi, Y.; Ding, S.; Wang, Z.; Li, L.; Wang, J.; Mehdizadeh, S.; Pilehvar, Y. Hydrogel-mediated tri-modal nanoplatform for localized colorectal cancer therapy via smart chemo–photothermal–radiotherapy. J. Biol. Eng. 2026 , 20 , 42..

Su, L.; Zhu, K.; Ge, X.; Wu, Y.; Zhang, J.; Wang, G.; Liu, D.; Chen, L.; Li, Q.; Chen, J.; Song, J. X-ray activated nanoprodrug for visualization of cortical microvascular alterations and NIR-II image-guided chemo-radiotherapy of glioblastoma. Nano Lett. 2024 , 24 , 3727−3736..

Sun, L.; Shen, F.; Tian, L.; Tao, H.; Xiong, Z.; Xu, J.; Liu, Z. ATP-responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity. Adv. Mater. 2021 , 33 , 2007910..

Liu, C.; Lin, R.; Lai, H.; Pi, F.; Xue, Q.; Chen, T.; He, W. Thermosensitive selenium hydrogel boosts antitumor immune response for hepatocellular carcinoma chemoradiotherapy. Nano Today 2023 , 50 , 101823..

Zhu, Y.; Zhang, S.; Lai, Y.; Pan, J.; Chen, F.; Wang, T.; Wang, F.; Xu, Z.; Yang, W.; Yu, H. Self-cooperative prodrug nanovesicles migrate immune evasion to potentiate chemoradiotherapy in head and neck cancer. Adv. Sci. 2022 , 9 , 2203263..

Chen, Y.; Liu, S.; Gao, P.; Pan, W.; Shi, M.; Wang, J.; Li, N.; Tang, B. Reprogramming tumor-immune cell communication with a radiosensitive nanoregulator for immunotherapy. Sci. China Mater. 2023 , 66 , 352−362..

Deng, Z.; Xi, M.; Zhang, C.; Wu, X.; Li, Q.; Wang, C.; Fang, H.; Sun, G.; Zhang, Y.; Yang, G.; Liu, Z. BiomineralizedMnO 2 nanoplatforms mediated delivery of immune checkpoint inhibitors with STING pathway activation to potent iate cancer radio-immunotherapy. ACS Nano 2023 , 17 , 4495−4506..

Graham, K.; Unger, E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int. J. Nanomed. 2018 , 13 , 6049−6058..

Zeng, W.; Liu, P.; Pan, W.; Singh, S. R.; Wei, Y. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015 , 356 , 263−267..

[Ma, J.; Li, N.; Wang, J.; Liu, Z.; Han, Y.; Zeng, Y. In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms. Exploration 2023, 3 , 20220161..

Chen, G.; Wu, K.; Li, H.; Xia, D.; He, T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front. Oncol. 2022 , 12 , 961637..

Rockwell, S.; Dobrucki, I. T.; Kim, E. Y.; Marrison, S. T.; Vu, V. T. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr. Mol. Med. 2009 , 9 , 442−458..

Gray, L. H.; Conger, A. D.; Ebert, M.; Hornsey, S.; Scott, O. C. A. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953 , 26 , 638−648..

Barker, H. E.; Paget, J. T. E.; Khan, A. A.; Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 2015 , 15 , 409−425..

Heckmann, M.; Douwes, K.; Peter, R.; Degitz, K. Vascular activation of adhesion molecule mRNA and cell surface expression by ionizing radiation. Exp. Cell Res. 1998 , 238 , 148−154..

Liu, Z.; Zhao, Q.; Zheng, Z.; Liu, S.; Meng, L.; Dong, L.; Jiang, X. Vascular normalization in immunotherapy: a promising mechanisms combined with radiotherapy. Biomed. Pharmacother. 2021 , 139 , 111607..

Baker, D. G.; Krochak, R. J. The response of the microvascular system to radiation: a review. Cancer Invest. 1989 , 7 , 287−294..

Ivey, J. W.; Bonakdar, M.; Kanitkar, A.; Davalos, R. V.; Verbridge, S. S. Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Lett. 2016 , 380 , 330−339..

Tamura, R.; Tanaka, T.; Akasaki, Y.; Murayama, Y.; Yoshida, K.; Sasaki, H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med. Oncol. 2019 , 37 , 2..

Wang, Q.; Liang, Q.; Dou, J.; Zhou, H.; Zeng, C.; Pan, H.; Shen, Y.; Li, Q.; Liu, Y.; Leong, D. T.; Jiang, W.; Wang, Y. Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nat. Nanotechnol. 2024 , 19 , 95−105..

Xie, J.; Gong, L.; Zhu, S.; Yong, Y.; Gu, Z.; Zhao, Y. Emerging strategies of nanomaterial-mediated tumor radiosensitization. Adv. Mater. 2019 , 31 , 1802244..

Jiang, H.; Wang, H.; De Ridder, M. Targeting antioxidant enzymes as a radiosensitizing strategy. Cancer Lett. 2018 , 438 , 154−164..

Tafani, M.; Sansone, L.; Limana, F.; Arcangeli, T.; De Santis, E.; Polese, M.; Fini, M.; Russo, M. A. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxid. Med. Cell. Longev. 2016 , 2016 , 3907147..

Zou, Z.; Chang, H.; Li, H.; Wang, S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis 2017 , 22 , 1321−1335..

Jia, S.; Ge, S.; Fan, X.; Leong, K. W.; Ruan, J. Promoting reactive oxygen species generation: a key strategy in nanosensitizer-mediated radiotherapy. Nanomedicine 2021 , 16 , 759−778..

Kennel, K. B.; Greten, F. R. Immune cell - produced ROS and their impact on tumor growth and metastasis. Redox Biol. 2021 , 42 , 101891..

Dabbour, N. M.; Salama, A. M.; Donia, T.; Al-Deeb, R. T.; Abd Elghane, A. M.; Badry, K. H.; Loutfy, S. A. Managing GSH elevation and hypoxia to overcome resistance of cancer therapies using functionalized nanocarriers. J. Drug Deliv. Sci. Technol. 2022 , 67 , 103022..

Sonveaux, P. ROS and radiotherapy: more we care. Oncotarget 2017 , 8 , 35482−35483..

Webb, B. A.; Chimenti, M.; Jacobson, M. P.; Barber, D. L. Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 2011 , 11 , 671−677..

Persi, E.; Duran-Frigola, M.; Damaghi, M.; Roush, W. R.; Aloy, P.; Cleveland, J. L.; Gillies, R. J.; Ruppin, E. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat. Commun. 2018 , 9 , 2997..

[Zheng, T.; Jäättelä, M.; Liu, B. pH gradient reversal fuels cancer progression. Int. J. Biochem. Cell 2020, 125 , 105796..

Bogdanov, A.; Bogdanov, A.; Chubenko, V.; Volkov, N.; Moiseenko, F.; Moiseyenko, V. Tumor acidity: from hallmark of cancer to target of treatment. Front. Oncol. 2022 , 12 , 979154..

[Mahoney, B. P.; Raghunand, N.; Baggett, B.; Gillies, R. J. Tumor acidity, ion trapping and chemotherapeutics: I. acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol . 2003, 66 , 1207−1218..

Sauvant, C.; Nowak, M.; Wirth, C.; Schneider, B.; Riemann, A.; Gekle, M.; Thews, O. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int. J. Cancer 2008 , 123 , 2532−2542..

Thews, O.; Gassner, B.; Kelleher, D. K.; Schwerd, G.; Gekle, M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006 , 8 , 143−152..

Hu, P.; Li, T.; Lin, J.; Qiu, M.; Wang, D.; Liu, Z.; Chen, Z.; Yang, L.; Zhang, X.; Zhao, Q.; Chen, Y.; Lu, Y.; Wu, Q.; Pu, H.; Zeng, Z.; Xie, D.;Ju, H.; Luo, H.; Xu, R. VDR–SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduction Targeted Ther. 2020 , 5 , 183..

Bristow, R. G.; Hill, R. P. Hypoxia, DNA repair and genetic instab ility. Nat. Rev. Cancer 2008 , 8 , 180−192..

Huntington, K. E.; Louie, A.; Zhou, L.; Seyhan, A. A.; Maxwell, A. W.; El-Deiry, W. S. Colorectal cancer extracellular acidosis decreases immune cell killing and is partially ameliorated by pH-modulating agents that modify tumor cell cytokine profiles. Am. J. Cancer Res. 2022 , 12 , 138−151..

Fischer, K.; Hoffmann, P.; Voelkl, S.; Meidenbauer, N.; Ammer, J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; Renner, K.; Timischl, B.; Mackensen, A.; Kunz-Schughart, L.; Andreesen, R.; Krause, S. W.; Kreutz, M. Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood 2007 , 109 , 3812−3819..

[Klaus, T.; Deshmukh, S. pH-responsive antibodies for therapeutic applications. J. Biomed. Sci . 2021, 28 , 11..

[Li, Z.; Huang, J.; Wu, J. pH-sensitive nanogels for drug delivery in cancer therapy. Biomater. Sci . 2021, 9 , 574−589..

Morarasu, S.; Morarasu, B. C.; Ghiarasim, R.; Coroaba, A.; Tiron, C.; Iliescu, R.; Dimofte, G. M. Targeted cancer therapy via pH-functionalized nanoparticles: a scoping review of methods and outcomes. Gels 2022 , 8 , 232..

Li, X.; Yue, R.; Guan, G.; Zhang, C.; Zhou, Y.; Song, G. Recent development of pH-responsive theranostic nanoplatforms for magnetic resonance imaging-guided cancer therapy. Exploration 2023 , 3 , 20220002..

[Le, A., in The heterogeneity of cancer metabolism , Springer Nature, 2021 , pp. 3−15..

[Oshima, N.; Ishida, R.; Kishimoto, S.; Beebe, K.; Brender, J. R.; Yamamoto, K.; Urban, D.; Rai, G.; Johnson, M. S.; Benavides, G. Dynamic imaging of LDH inhibition in tumors reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy. Cell Rep . 2020, 30 , 1798−1810..

Koltai, T. Triple-edged therapy targeting intracellular alkalosis and extracellular acidosis in cancer. Semin. Cancer Biol. 2017 , 43 , 139−146..

Pillai, S. R.; Damaghi, M.; Marunaka, Y.; Spugnini, E. P.; Fais, S.; Gillies, R. J. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev. 2019 , 38 , 205−222..

Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011 , 144 , 646−674..

Heldin, C. H.; Rubin, K.; Pietras, K.; Östman, A. High interstitial fluid pressure — an obstacle in cancer therapy. Nat. Rev. Cancer 2004 , 4 , 806−813..

DuFort, C. C.; DelGiorno, K. E.; Carlson, M. A.; Osgood, R. J.; Zhao, C.; Huang, Z.; Thompson, C. B.; Connor, R. J.; Thanos, C. D.; Scott Brockenbrough, J.; Provenzano, P. P.; Frost, G. I.; Michael Shepard, H.; Hingorani, S. R. Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophys. J. 2016 , 110 , 2106−2119..

Cirri, P.; Chiarugi, P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012 , 31 , 195−208..

Liu, H.; Zhao, H.; Sun, Y. Tumor microenvironment and cellular senescence: understanding therapeutic resistance and harnessing strategies. Semin. Cancer Biol. 2022 , 86 , 769−781..

Goenka, A.; Khan, F.; Verma, B.; Sinha, P.; Dmello, C. C.; Jogalekar, M. P.; Gangadaran, P.; Ahn, B. C. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun. 2023 , 43 , 525−561..

Emons, G.; Spitzner, M.; Reineke, S.; Möller, J.; Auslander, N.; Kramer, F.; Hu, Y.; Beissbarth, T.; Wolff, H. A.; Rave-Fränk, M.; Heßmann, E.; Gaedcke, J.; Ghadimi, B. M.; Johnsen, S. A.; Ried, T.; Grade, M. Chemoradiotherapy resistance in colorectal cancer cells is mediated by Wnt/ β -catenin signaling. Mol. Cancer Res. 2017 , 15 , 1481−1490..

Sun, Y.; Campisi, J.; Higano, C.; Beer, T. M.; Porter, P.; Coleman, I.; True, L.; Nelson, P. S. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 2012 , 18 , 1359−1368..

Chen, F.; Long, Q.; Fu, D.; Zhu, D.; Ji, Y.; Han, L.; Zhang, B.; Xu, Q.; Liu, B.; Li, Y.; Wu, S.; Yang, C.; Qian, M.; Xu, J.; Li u, S.; Cao, L.; Chin, Y. E.; Lam, E. W. F.; Coppé, J. P.; Sun, Y. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. Nat. Commun. 2018 , 9 , 4315..

Laberge, R. M.; Sun, Y.; Orjalo, A. V.; Patil, C. K.; Freund, A.; Zhou, L.; Curran, Samuel C.; Davalos, A. R.; Wilson-Edell, K. A.; Liu, S.; Limbad, C.; Demaria, M.; Li, P.; Hubbard, G. B.; Ikeno, Y.; Javors, M.; Desprez, P. Y.; Benz, C. C.; Kapahi, P.; Nelson, P. S.; Campisi, J. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 2015 , 17 , 1049−1061..

Zhang, B.; Fu, D.; Xu, Q.; Cong, X.; Wu, C.; Zhong, X.; Ma, Y.; Lv, Z.; Chen, F.; Han, L.; Qian, M.; Chin, Y. E.; Lam, E. W. F.; Chiao, P.; Sun, Y. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. Nat. Commun. 2018 , 9 , 1723..

Rajbhandary, S.; Dhakal, H.; Shrestha, S. Tumor immune microenvironment (TIME) to enhance antitumor immunity. Eur. J. Med. Res. 2023 , 28 , 169..

Khalaf, K.; Hana, D.; Chou, J. T.; Singh, C.; Mackiewicz, A.; Kaczmarek, M. Aspects of the tumor microenvironment involved in imm une resistance and drug resistance. Front. Immunol. 2021 , 12 , 656364..

Sridharan, V.; Margalit, D. N.; Lynch, S. A.; Severgnini, M.; Zhou, J.; Chau, N. G.; Rabinowits, G.; Lorch, J. H.; Hammerman, P. S.; Hodi, F. S.; Haddad, R. I.; Tishler, R. B.; Schoenfeld, J. D. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br. J. Cancer 2016 , 115 , 252−260..

Burnette, B. C.; Liang, H.; Lee, Y.; Chlewicki, L.; Khodarev, N. N.; Weichselbaum, R. R.; Fu, Y. X.; Auh, S. L. The efficacy of radiotherapy relies upon induction of type I interferon–dependent innate and adaptive immunity. Cancer Res. 2011 , 71 , 2488−2496..

Schuler, P. J.; Harasymczuk, M.; Schilling, B.; Saze, Z.; Strauss, L.; Lang, S.; Johnson, J. T.; Whiteside, T. L. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin. Cancer. Res. 2013 , 19 , 6585−6596..

Al-Taei, S.; Banner, R.; Powell, N.; Evans, M.; Palaniappan, N.; Tabi, Z.; Man, S. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunol. Immunother. 2013 , 62 , 1821−1830..

Van Meir, H.; Nout, R. A.; Welters, M. J. P.; Loof, N. M.; De Kam, M. L.; Van Ham, J. J.; Samuels, S.; Kenter, G. G.; Cohen, A. F.; Melief, C. J. M. Impact of (chemo)radiotherapy on immune cell composition and functionin cervical cancer patients. Oncoimmunology 2017 , 6 , e1267095..

Bai, R.; Cui, J. Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing. Front. Immunol. 2022 , 13 , 890166..

Li, Z.; Di, C.; Li, S.; Yang, X.; Nie, G. Smart nanotherapeutic targeting of tumor vasculature. Acc. Chem. Res. 2019 , 52 , 2703−2712..

Horsman, M. R.; Siemann, D. W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006 , 66 , 11520−11539..

Iversen, A. B.; Busk, M.; Horsman, M. R. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol. 2013 , 52 , 1320−1326..

Li, L.; Wartchow, C. A.; Danthi, S. N.; Shen, Z.; Dechene, N.; Pease, J.; Choi, H. S.; Doede, T.; Chu, P.; Ning, S.; Lee, D. Y.; Bednarski, M. D.; Knox, S. J. A novel antiangiogenesis therapy using an integrin antagonist or anti–Flk-1 antibody coated 90 Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol., Phys. 2004 , 58 , 1215−1227..

Zheng, R.; Li, F.; Li, F.; Gong, A. Targeting tumor vascularization: promising strategies for vascular normalization. J. Cancer Res. Clin. Oncol. 2021 , 147 , 2489−2505..

El Alaoui-Lasmaili, K.; Faivre, B. Antiangiogenic therapy: markers of response, “normalization” and resistance. Crit. Rev. Oncol. Hematol. 2018 , 128 , 118−129..

McGee, M. C.; Hamner, J. B.; Williams, R. F.; Rosati, S. F.; Sims, T. L.; Ng, C. Y.; Gaber, M. W.; Calabrese, C.; Wu, J.; Nathwani, A. C.; Duntsch, C.; Merchant, T. E.; Davidoff, A. M. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol., Phys. 2010 , 76 , 1537−1545..

Magnussen, A. L.; Mills, I. G. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br. J. Cancer 2021 , 125 , 324−336..

Yin, W.; Qiang, M.; Ke, W.; Han, Y.; Mukerabigwi, J. F.; Ge, Z. Hypoxia-responsive block copolymer radiosensitizers as anticancer drug nanocarriers for enhanced chemoradiotherapy of bulky solid tumors. Biomaterials 2018 , 181 , 360−371..

Prasad, P.; Gordijo, C. R.; Abbasi, A. Z.; Maeda, A.; Ip, A.; Rauth, A. M.; DaCosta, R. S.; Wu, X. Y. Multifunctional albumin–MnO 2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. ACS Nano 2014 , 8 , 3202−3212..

Feng, L.; Dong, Z.; Liang, C.; Chen, M.; Tao, D.; Cheng, L.; Yang, K.; Liu, Z. Iridium nanocrystals encapsulated liposomes as near-infrared light controllable nanozymes for enhanced cancer radiotherapy. Biomaterials 2018 , 181 , 81−91..

Tremi, I.; Spyratou, E.; Souli, M.; Efstathopoulos, E. P.; Makropoulou, M.; Georgakilas, A. G.; Sihver, L. Requirements for designing an effective metallic nanoparticle (NP)-boosted radiation therapy (RT). Cancer 2021 , 13 , 3185..

Setua, S.; Ouberai, M.; Piccirillo, S. G.; Watts, C.; Welland, M. Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma. Nanoscale 2014 , 6 , 10865−10873..

Pivovarov, N. A.; Kolmanovich, D. D.; Chukavin, N. N.; Savintseva, I. V.; Popova, N. R.; Shemyakov, A. E.; Filippova, A. D.; Teplonogova, M. A.; Yurkovskaya, A. V.; Zhukov, I. V.; Akkizov, A. Y.; Popov, A. L. Novel cerium- and terbium-doped gadolinium fluoride nanoparticles as radiosensitizers with pronounced radiocatalytic activity. Biomedicines 2025 , 13 , 1537..

Zwiehoff, S.; Johny, J.; Behrends, C.; Landmann, A.; Mentzel, F.; Bäumer, C.; Kröninger, K.; Rehbock, C.; Timmermann, B.; Barcikowski, S. Enhancement of proton therapy efficiency by noble metal nanoparticles is driven by the number and chemical activity of surface atoms. Small 2022 , 18 , 2106383..

Yang, G.; Ji, J.; Liu, Z. Multifunctional MnO 2 nanoparticles for tumor microenvironment modulation and cancer therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2021 , 13 , e1720..

Rahman, M.; Kabir, M.; Islam, T.; Wang, Y.; Meng, Q.; Liu, H.; Chen, S.; Wu, S. Curcumin-loaded ZIF-8 nanomaterials: exploring drug loading efficiency and biomedical performance. ACS Omega 2025 , 10 , 3067−3079..

Young, O.; Ngo, N.; Lin, L.; Stanbery, L.; Creeden, J. F.; Hamouda, D.; Nemunaitis, J. Folate receptor as a biomarker and therapeutic target in solid tumors. Curr. Probl. Cancer 2023 , 47 , 100917..

Hansen, M. F.; Greibe, E.; Skovbjerg, S.; Rohde, S.; Kristensen, A. C. M.; Jensen, T. R.; Stentoft, C.; Kjær, K. H.; Kronborg, C. S.; Martensen, P. M. Folic acid mediates activation of the pro-oncogene STAT3 via the folate receptor alpha. Cell. Signal. 2015 , 27 , 1356−1368..

Girigoswami, K.; Girigoswami, A.Breast cancer progression and its theranostic management via folate-directed targeting of glycoprotein receptor. Med. Sci. 2025 , 13 , 275..

Liu, X.; Yuan, Z.; Tang, Z.; Chen, Q.; Huang, J.; He, L.; Chen, T. Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting n anotherapeutics. Biomater. Sci. 2021 , 9 , 4691−4700..

Farran, B.; Montenegro, R. C.; Kasa, P.; Pavitra, E.; Huh, Y. S.; Han, Y. K.; Kamal, M. A.; Nagaraju, G. P.; Rama Raju, G. S. Folate-conjugated nanovehicles: strategies for cancer therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 2020 , 107 , 110341..

Sakunrangsit, N.; Khantasup, K.; Pornputtipong, N.; Suppipat, K.; Hirankarn, N.; Tawinwung, S. Human VH-antibody-based CAR T cells targeting folate receptor-alpha show enhanced persistence and reduced T-cell exhaustion against ovarian cancer. Biomed. Pharmacother. 2026 , 197 , 119169..

Campbell, I. D.; Humphries, M. J. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 2011 , 3 , a004994..

LaFlamme, S. E.; Auer, K. L. Integrin signaling. Semin. Cancer Biol. 1996 , 7 , 111−118..

Brooks, P. C.; Montgomery, A. M. P.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Integrin α v β 3 antagonists p romote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994 , 79 , 1157−1164..

Wang, K.; Li, Z. L.; Huang, L. Y.; Yao, C. J.; Crawford, D. R.; Wang, C. Y.; Mo, J. K.; Shih, Y. J.; Lin, H. Y.; WhangPeng, J. Integrin α v β 3 as a non-genomic estrogen receptor in breast cancer for signaling pathways and crosstalk. Cells 2025 , 14 , 1832..

Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 1996 , 12 , 697−715..

Videtic, G. M. M.; Fisher, B. J.; Perera, F. E.; Bauman, G. S.; Kocha, W. I.; Taylor, M.; Vincent, M. D.; Plewes, E. A.; Engel, C. J.; Stitt, L. W. Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int. J. Radiat. Oncol. Biol., Phys. 1998 , 42 , 319−324..

[Valencia-Lazcano, A. A.; Hassan, D.; Pourmadadi, M.; Shamsabadipour, A.; Behzadmehr, R.; Rahdar, A.; Medina, D. I.; Díez-Pascual, A. M. 5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy. Eur. J. Med. Chem . 2023, 246 , 114995..

Xue, C.; Zhang, X.; Yu, W.; Lin, H.; Zhang, J.; Liu, J.; Weng, Z.; Ouyang, M.; Lin, X. GLI2-HRD1 axis facilitates 5-FU resistance in gastric cancer cells by regulating ubiquitination degradation of UCK2. Transl. Oncol. 2025 , 58 , 102423..

Lv, B.; Wang, Y.; Ma, D.; Cheng, W.; Liu, J.; Yong, T.; Chen, H.; Wang, C. Immunotherapy: reshape the tumor immune microenvironment. Front. Immunol. 2022 , 13 , 844142..

McFarland, H. I.; Puig, M.; Grajkowska, L. T.; Tsuji, K.; Lee, J. P.; Mason, K. P.; Verthelyi, D.; Rosenberg, A. S. Regulatory T cells in γ irradiation-induced immune suppression. PLoS One 2012 , 7 , e39092..

Mougiakakos, D.; Johansson, C. C.; Jitschin, R.; Böttcher, M.; Kiessling, R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood 2011 , 117 , 857−861..

Suzuki, E.; Kapoor, V.; Jassar, A. S.; Kaiser, L. R.; Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1 + /CD11b + myeloid suppressor cells i n tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer. Res. 2005 , 11 , 6713−6721..

[Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rébé, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell–dependent antitumor immunity. Cancer Res . 2010, 70 , 3052−3061..

Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Criollo, A.; Ortiz, C.; Lidereau, R.; Mariette, C.; Chaput, N.; Mira, J. P.; Delaloge, S.; André, F.; Tursz, T.; Kroemer, G.; Zitvogel, L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 2007 , 220 , 47−59..

Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J. P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; André, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007 , 13 , 1050−1059..

Apetoh, L.; Tesniere, A.; Ghiringhelli, F.; Kroemer, G.; Zitvogel, L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008 , 68 , 4026−4030..

Kono, K.; Mimura, K.; Kiessling, R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis. 2013 , 4 , e688..

Moridikia, A.; Montazersaheb, S.; Molavi, O. Manipulation of tumor microenvironment by induction of immunogenic cell death and immune check point inhibitors for enhancing the efficacy of cancer treatments. Biomed. Pharmacother. 2026 , 196 , 119118..

Pointer, K. B.; Pitroda, S. P.; Weichselbaum, R. R. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer 2022 , 8 , 9−20..

Feng, C. H.; Mell, L. K.; Sharabi, A. B.; McHale, M.; Mayadev, J. S. Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer. Semin. Radiat. Oncol. 2020 , 30 , 273−280..

Dong, Q.; Xue, T.; Yan, H.; Liu, F.; Liu, R.; Zhang, K.; Chong, Y.; Du, J.; Zhang, H. Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy. J. Nanobiotechnol. 2023 , 21 , 395..

Zhou, J.; Zhang, Y.; Dong, F.; Matsuyama, K.; Tanaka, Y.; Wu, L. Mechanisms of tumor radiosensitization: a perspective of nano-radiotherapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2025 , 17 , e70035..

Rosenthal, D. I.; Yom, S. S.; Liu, L.; Machtay, M.; Algazy, K.; Weber, R. S.; Weinstein, G. S.; Chalian, A. A.; Miller, L. K.; Rockwell, K.; Tonda, M.; Schnipper, E.; Hershock, D. A phase I study of SPI-077 (stealth® liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest. New Drugs 2002 , 20 , 343−349..

Koukourakis, M. I.; Giatromanolaki, A.; Pitiakoudis, M.; Kouklakis, G.; Tsoutsou, P.; Abatzoglou, I.; Panteliadou, M.; Sismanidou, K.; Sivridis, E.; Boulikas, T. Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int. J. Radiat. Oncol. Biol., Phys. 2010 , 78 , 150−155..

Zeng, J.; Cui, X.; Cheng, L.; Chen, Y.; Du, X.; Sheng, L. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Cancer Radiother. 2021 , 25 , 441−446..

Chen, G.; Sheng, L.; Du, X. Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma. Cancer Chemother. Pharmacol. 2018 , 82 , 505−510..

Beier, C. P.; Schmid, C.; Gorlia, T.; Kleinletzenberger, C.; Beier, D.; Grauer, O.; Steinbrecher, A.; Hirschmann, B.; Brawanski, A.; Dietmaier, C.; Jauch-Worley, T.; Kölbl, O.; Pietsch, T.; Proescholdt, M.; Rümmele, P.; Muigg, A.; Stockhammer, G.; Hegi, M.; Bogdahn, U.; Hau, P. RNOP-09: PEGylated liposomal doxorubicin and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma: a phase II study. BMC Cancer 2009 , 9 , 308..

Ananda, S.; Nowak, A. K.; Cher, L.; Dowling, A.; Brown, C.; Simes, J.; Rosenthal, M. A. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J. Clin. Neurosci. 2011 , 18 , 1444−1448..

Tsujimoto, A.; Sudo, K.; Nakamura, K.; Kita, E.; Hara, R.; Takayama, W.; Ishii, H.; Yamaguchi, T. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Sci. Rep. 2019 , 9 , 16187..

Philip, P. A.; Lacy, J.; Portales, F.; Sobrero, A.; Pazo-Cid, R.; Manzano Mozo, J. L.; Kim, E. J.; Dowden, S.; Zakari, A.; Borg, C.; Terrebonne, E.; Rivera, F.; Sastre, J.; Bathini, V.; López-Trabada, D.; Asselah, J.; Saif, M. W.; Shiansong Li, J.; Ong, T. J.; Nydam, T.; Hammel, P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet. Gastroenterol. 2020 , 5 , 285−294..

Jiang, H.; Li, Q.; Chen, B.; Xi, M.; Makelike, K.; Liu, S.; Hu, Y.; Zhu, Y. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Med. 2023 , 12 , 15187−15198..

Oppelt, P.; Ley, J.; Daly, M.; Rich, J.; Paniello, R.; Jackson, R. S.; Pipkorn, P.; Liu, J.; Gay, H.; Palka, K.; Neupane, P.; Powell, S.; Spanos, W. C.; Gitau, M.; Zevallos, J.; Thorstad, W.; Adkins, D. Nab-paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and ra diation (Arm 2) for locally advanced head and neck squamous cell carcinoma: a multicenter, nonrandomized phase 2 trial. Med. Oncol. 2021 , 38 , 35..

Weiss, J.; Gilbert, J.; Deal, A. M.; Weissler, M.; Hilliard, C.; Chera, B.; Murphy, B.; Hackman, T.; Liao, J. J.; Grilley Olson, J.; Hayes, D. N. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol. 2018 , 84 , 46−51..

Adkins, D.; Ley, J.; Michel, L.; Wildes, T. M.; Thorstad, W.; Gay, H. A.; Daly, M.; Rich, J.; Paniello, R.; Uppaluri, R.; Jackson, R.; Trinkaus, K.; Nussenbaum, B. Nab-paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncol. 2016 , 61 , 1−7..

Tanaka, H.; Hasegawa, Y.; Makiguchi, T.; Okumura, F.; Tabe, C.; Shiratori, T.; Ishioka, Y.; Itoga, M.; Taima, K.; Yokouchi, J.; Hatayama, Y.; Aoki, M.; Tasaka, S. A phase I/II study of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non–small-cell lung cancer. Clin. Lung Cancer 2021 , 22 , 42−48..

Omori, S.; Harada, H.; Mori, K.; Hisamatsu, Y.; Tsuboguchi, Y.; Yoshioka, H.; Morinaga, R.; Daga, H.; Kurata, T.; Takahashi, T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest. New Drugs 2022 , 40 , 106−114..

Kaira, K.; Tomizawa, Y.; Imai, H.; Sakurai, R.; Matsuura, M.; Yoshii, A.; Ochiai, M.; Kotake, M.; Ebara, T.; Saitoh, J. I.; Sunaga, N.; Minato, K.; Saito, R.; Hisada, T. Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2017 , 79 , 165−171..

Hasegawa, T.; Futamura, Y.; Horiba, A.; Yoshida, T.; Suzuki, T.; Kato, T.; Kaito, D.; Ohno, Y.; Iida, T.; Hayashi, S.; Sawa, T. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non–small-cell lung cancer. J. Radiat. Res. 2016 , 57 , 50−54..

Kawano, Y.; Sasaki, T.; Yamaguchi, H.; Hirano, K.; Horiike, A.; Satouchi, M.; Hosokawa, S.; Morinaga, R.; Komiya, K.; Inoue, K.; Fujita, Y.; Toyozawa, R.; Kimura, T.; Takahashi, K.; Nishikawa, K.; Kishimoto, J.; Nakanishi, Y.; Okamoto, I. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advance d non–small cell lung cancer. Lung Cancer 2018 , 125 , 136−141..

Sanoff, H. K.; Moon, D. H.; Moore, D. T.; Boles, J.; Bui, C.; Blackstock, W.; O'Neil, B. H.; Subramaniam, S.; McRee, A. J.; Carlson, C.; Lee, M. S.; Tepper, J. E.; Wang, A. Z. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomed. Nanotechnol. Biol. Med. 2019 , 18 , 189−195..

Verry, C.; Dufort, S.; Villa, J.; Gavard, M.; Iriart, C.; Grand, S.; Charles, J.; Chovelon, B.; Cracowski, J. L.; Quesada, J. L.; Mendoza, C.; Sancey, L.; Lehmann, A.; Jover, F.; Giraud, J. Y.; Lux, F.; Crémillieux, Y.; McMahon, S.; Pauwels, P. J.; Cagney, D.; Berbeco, R.; Aizer, A.; Deutsch, E.; Loeffler, M.; Le Duc, G.; Tillement, O.; Balosso, J. Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother. Oncol. 2021 , 160 , 159−165..

Boux, F.; Mercier, A.; Talba, D.; Giraud, J.-Y.; Dufort, S.; Seddik, K.; Grand, S.; Gataleta, M.; Leboucher, A.; Pietras, J.; De Beaumont, O.; Le Duc, G.; Verry, C. Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases. J. Neurooncol. 2026 , 177 , 91..

Chargari, C.; Maury, P.; Texier, M.; Genestie, C.; Morice, P.; Bockel, S.; Gouy, S.; Ba, M.; Achkar, S.; Lux, F.; Tillement, O.; Dufort, S.; Duc, G. L. E.; Debeaumont, O.; Massard, C.; Maulard, A.; Porcel, E.; Bahleda, R.; Ammari, S.; Morel, D.; Espenel, S.; Pautier, P.; Robert, C.; Deutsch, E. Theragnostic gadolinium-based nanoparticles safely augment X-ray radiation effects in patients with cervical cancer. ACS Nano 2024 , 18 , 16516−16529..

Thivat, E.; Casile, M.; Moreau, J.; Molnar, I.; Dufort, S.; Seddik, K.; Le Duc, G.; De Beaumont, O.; Loeffler, M.; Durando, X.; Biau, J. Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). BMC Cancer 2023 , 23 , 344..

Sapir, E.; Pfeffer, R.; Wygoda, M.; Purim, O.; Levy, A.; Corn, B.; Amitay, Y.; Ohana, P.; Gabizon, A. Pegylated liposomal mitomycin c lipidic prodrug in combination with external beam radiation therapy in patients with advanced cancer: a phase 1B study. Int. J. Radiat. Oncol. Biol. Phys. 2023 , 117 , 64−73..

Le Tourneau, C.; Liem, X.; Nguyen, F.; Deraedt, S.; Salas, S.; Calugaru, V.; Serrahima, M. P.; Wong Hee Kam, S.; Hoffmann, C.; Lesnik, M.; Blanchard, P.; Poissonnet, G.; Bozec, A .; Saada-Bouzid, E.; Jégoux, F.; Castelli, J.; Devisetty, K.; Lelonge, Y.; Jadaud, E.; Houdas, L.; Debard, A.; Vivar, O. I.; Finzi, L.; Serra, A.; Linares, I.; Arranz Obispo, C.; Thariat, J.; Rambeau, A.; Fakhry, N.; Santini, L.; Giralt, J.; Braña García, I.; Barba, M. S.; Gorphe, P.; Helfferich, F.; Herczeg, A.; Papai, Z.; Fijuth, J.; Takácsi-Nagy, Z. Intratumoral radioenhancer nanoparticle NBTXR3 followed by radiotherapy in head and neck cancer: a phase 1 dose-expansion nonrandomized clinical trial. JAMA Otolaryngol. 2026 , 152 , 284−293..

Le Tourneau, C.; Takácsi-Nagy, Z.; Nuyts, S.; Thureau, S.; Liu, F.; Hoffmann, C.; Hackman, T. G.; Lesnik, M.; Debard, A.; Finzi, L.; Devisetty, K.; Vivar, O. I.; Farber, L. A.; Nguyen, F.; Liem, X.; Natelauri, E.; Psyrri, A.; Burian, M.; Yu, J.; Yom, S. S. Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC. Future Oncol. 2025 , 21 , 1489−1499..

Miller, S. M.; Wang, A. Z. Nanomedicine in chemoradiation. Ther. Deliv. 2013 , 4 , 239−250..

Yi, Q.; Liu, C.; Cui, Y.; Yang, Y.; Li, Y.; Fan, X.; Wu, K. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: a retrospective analysis. Cancer Med. 2023 , 12 , 6477−6487..

Israel, V. P.; Garcia, A. A.; Roman, L.; Muderspach, L.; Burnett, A.; Jeffers, S.; Muggia, F. M. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol. Oncol. 2000 , 78 , 143−147..

Kouloulias, V. E.; Dardoufas, C. E.; Kouvaris, J. R.; Gennatas, C. S.; Polyzos, A. K.; Gogas, H. J.; Sandilos, P. H.; Uzunoglu, N. K.; Malas, E. G.; Vlahos, L. J. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin. Cancer. Res. 2002 , 8 , 374−382..

Oh, W. K.; Kaplan, I. D.; Febbo, P.; Prisby, J.; Manola, J.; Kaufman, D. S.; Kantoff, P. W. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. Am. J. Clin. Oncol. 2003 , 26 , 312−316..

Koukourakis, M. I.; Koukouraki, S.; Giatromanolaki, A.; Archimandritis, S. C.; Skarlatos, J.; Beroukas, K.; Bizakis, J. G.; Retalis, G.; Karkavitsas, N.; Helidonis, E. S. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non–small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 1999 , 17 , 3512−3521..

[Wiedenmann, N.; Valdecanas, D.; Hunter, N.; Hyde, S.; Buchholz, T. A.; Milas, L.; Mason, K. A. 130-nm albumin–bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin. Cancer. Res . 2007, 13 , 1868−1874..

Madappa, K.; Niu, J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des. Devel. Ther. 2015 , 9 , 3767−3777..

Yardley, D. A. Nab-paclitaxel mechanisms of action and delivery. J. Control. Release 2013 , 170 , 365−372..

Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005 , 23 , 7794−7803..

Frese, K. K.; Neesse, A.; Cook, N.; Bapiro, T. E.; Lolkema, M. P.; Jodrell, D. I.; Tuveson, D. A. Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levelsin a mouse model of pancreatic cancer. Cancer Discov. 2012 , 2 , 260−269..

Zong, Y.; Wu, J.; Shen, K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget 2017 , 8 , 17360−17372..

Arscott, W. T.; Nead, K. T.; Bear, A.; Venigalla, S.; Shabason, J.; Lukens, J. N.; Plastaras, J. P.; Wojcieszynski, A.; Metz, J.; O’Hara, M. Concurrent nab-paclitaxel and radiotherapy: novel radiosensitization for borderline resectable or unresectable pancreatic cancer. Am. J. Clin. Oncol. 2021 , 44 , 469−474..

Takahashi, H.; Akita, H.; Ioka, T.; Wada, H.; Tomokoni, A.; Asukai, K.; Ohue, M.; Yano, M.; Ishikawa, O. Phase I trial evaluating the safety of preoperative gemcitabine/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas 2018 , 47 , 1135−1141..

[Tian, X.; Nguyen, M.; Foote, H. P.; Caster, J. M.; Roche, K. C.; Peters, C. G.; Wu, P.; Jayaraman, L.; Garmey, E. G.; Tepper, J. E.; Eliasof, S.; Wang, A. Z. CRLX101, a nanoparticle–drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1 α. Cancer Res . 2017, 77 , 1 12−122..

Du, Y.; Sun, H.; Lux, F.; Xie, Y.; Du, L.; Xu, C.; Zhang, H.; He, N.; Wang, J.; Liu, Y.; Leduc, G.; Doussineau, T.; Ji, K.; Wang, Q.; Lin, Z.; Wang, Y.; Liu, Q.; Tillement, O. Radiosensitization effect of AGuIX, a gadolinium-based nanoparticle, in nonsmall cell lung cancer. ACS Appl. Mater. Interfaces 2020 , 12 , 56874−56885..

Wang, J.; Liu, M.; Zhang, X.; Wang, X.; Xiong, M.; Luo, D. Stimuli-responsive linkers and their application in molecular imaging. Exploration 2024 , 4 , 20230027..

[Gabizon, A.; Shmeeda, H.; Tahover, E.; Kornev, G.; Patil, Y.; Amitay, Y.; Ohana, P.; Sapir, E.; Zalipsky, S. Development of promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: from bench to bedside. Adv. Drug Delivery Rev . 2020, 154−155 , 13−26..

Amitay, Y.; Shmeeda, H.; Patil, Y.; Gorin, J.; Tzemach, D.; Mak, L.; Ohana, P.; Gabizon, A. Pharmacologic studies of a prodrug of mitomycin c in pegylated liposomes (promitil®): high stability in plasma and rapid thiolytic prodrug activation in tissues. Pharm. Res. 2016 , 33 , 686−700..

Tian, X.; Warner, S. B.; Wagner, K. T.; Caster, J. M.; Zhang, T.; Ohana, P.; Gabizon, A. A.; Wang, A. Z. Preclinical evaluation of promitil, a radiation-responsive liposomal formulation of mitomycin c prodrug, in chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2016 , 96 , 547−555..

Molinaro, M.; Skrodzki, D.; Pan, D. Chemoradiotherapy and nanomedicine: drug mechanisms and delivery systems. Wiley Interdiscip. Rev.:Nanomed. Nanobiotechnol. 2024 , 16 , e1984..

Bienassis, C.; Vivar, O. I.; Hu, Y.; Da silva, J.; Darmon, A.; Marill, J.; Anesary, N. M.; Schmitt, P.; Levy, L.; Welsh, J.; Prezado, Y.; Megnin-Chanet, F.; Paris, S. The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity. J. Exp. Clin. Cancer Res. 2025 , 44 , 320..

Wang, R.; Liu, S.; Chen, B.; Xi, M. Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancers (Basel) 2022 , 14 , 5168..